Art

J-GLOBAL ID：201302276198359432   Reference number：13A0362729

Impact of Genetic Variation in Breast Cancer Resistance Protein (BCRP/ABCG2) on Sunitinib Pharmacokinetics

スニチニブの薬物動態に対する乳癌耐性蛋白質(BCRP/ABCG2)の遺伝子変異の影響

Author (8)： MIZUNO Tomoyuki (Dep. of Pharmacy, Kyoto Univ. Hospital) ,  FUKUDO Masahide (Dep. of Pharmacy, Kyoto Univ. Hospital) ,  TERADA Tomohiro (Dep. of Pharmacy, Kyoto Univ. Hospital) ,  KAMBA Tomomi (Dep. of Urology, Graduate School of Medicine, Kyoto Univ.) ,  NAKAMURA Eijiro (Dep. of Urology, Graduate School of Medicine, Kyoto Univ.) ,  OGAWA Osamu (Dep. of Urology, Graduate School of Medicine, Kyoto Univ.) ,  INUI Ken-ichi (Dep. of Pharmacy, Kyoto Univ. Hospital) ,  KATSURA Toshiya (Dep. of Pharmacy, Kyoto Univ. Hospital)
Material： Drug Metabolism and Pharmacokinetics  (Drug Metab Pharmacokinet)
Volume： 27  Issue： 6  Page： 631-639 (J-STAGE)  Publication year： 2012 
JST Material Number： X0758A  ISSN： 1347-4367  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： ABCB1 ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=13A0362729&from=J-GLOBAL&jstjournalNo=X0758A") }}

JST classification (1)： Basic research of antitumor(=antineoplastic)drugs  (GW16010A)

Substance index (1)： Sunitinib

Reference (42)：

• 1) Chow, L. Q. and Eckhardt, S. G.: Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol., 25: 884–896 (2007).
• 2) Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., Chen, I., Bycott, P. W., Baum, C. M. and Figlin, R. A.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med., 356: 115–124 (2007).
• 3) Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., Garcia-del-Muro, X., Sosman, J. A., Solska, E., Wilding, G., Thompson, J. A., Kim, S. T., Chen, I., Huang, X. and Figlin, R. A.: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol., 27: 3584–3590 (2009).
• 4) Uemura, H., Shinohara, N., Yuasa, T., Tomita, Y., Fujimoto, H., Niwakawa, M., Mugiya, S., Miki, T., Nonomura, N., Takahashi, M., Hasegawa, Y., Agata, N., Houk, B., Naito, S. and Akaza, H.: A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: Insights into the treatment, efficacy and safety. Jpn. J. Clin. Oncol., 40: 194–202 (2010).
• 5) Hong, M. H., Kim, H. S., Kim, C., Ahn, J. R., Chon, H. J., Shin, S. J., Ahn, J. B., Chung, H. C. and Rha, S. Y.: Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res. Treat., 41: 67–72 (2009).

Terms in the title (6)： スニチニブ ,  薬物動態 ,  乳癌耐性蛋白質 ,  BCRP ,  ABCG2 ,  遺伝子変異